IGH/BCL2 Translocation, Dual Fusion
This is a recurrent rearrangement of IGH in CLL1 and is cytogenetically indistinguishable from the t(14;18) translocation observed in follicular lymphoma.
The translocation (t(14;18)(q32.33;q21.33)) is thought to be brought about by an error in the joining function of the IGH gene, mediated by the observation that both IGH and BCL2 are arranged next to each other in 3D space in normal B lymphocytes2. The translocation breakpoint at the end of the Joining (J) segment, and the subsequent fusion of the BCL2 gene to this region, results in the BCL2 gene coming under the regulatory control of those processes normally involved in maintenance of IGH gene activity. The protein encoded by the BCL2 gene has been shown to be involved in the regulation of apoptosis.
In our hands, Cytocell FISH probes, have proven to be of the highest quality with bright, easy to interpret signals, thus providing confidence in our results. Cytocell’s customer support is outstanding, as their staff are extremely knowledgeable and truly care about their customers and their customers’ needs. Jennie Thurston, Director of Cytogenetics at Carolinas Pathology Group
1. Baseggio et al., Br J Haematol. 2012 Aug;158(4):489-98
2. Roix et al., Nature Genetics 2003;34(3):287-91
- Area of Interest*
This product is intended to be used on Carnoy’s solution (3:1 methanol/acetic acid) fixed haematological samples.
*Disease information supported by the literature and is not a reflection of the intended purpose of this product.